Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

gar control," said John Amatruda, M.D., vice president, clinical research, Merck & Co., Inc. "This study examines the clinical effect of initial combination therapy with JANUVIA and metformin, the two drugs comprising JANUMET, over one year."

An important predictive factor of the magnitude of A1C reduction in response to anti-hyperglycemic therapy is a patient's starting level of A1C. In a subgroup analysis of patients grouped by severity of starting baseline A1C, treatment with JANUVIA 50 mg/metformin 1000 mg twice daily demonstrated increasing mean A1C reductions from baseline the higher the baseline A1C. A mean reduction of 3.1 percent was seen in patients with baseline A1C of 10 percent or more (n=17), while reductions of 2.2 percent, 1.7 percent, and 1.0 percent were seen with baseline A1C values of nine to 10 percent, eight to nine percent, and less than eight percent, respectively.

Investigational study showed JANUVIA significantly improved blood sugar control when added to sulfonylurea or to sulfonylurea and metformin vs. sulfonylurea or sulfonylurea and metformin alone (Poster #535-P; Study #035)

In this study, which was designed to examine the efficacy and safety of JANUVIA in patients with type 2 diabetes whose blood glucose levels were inadequately controlled (A1C levels of 7.5 percent to 10.5 percent) on a sulfonylurea (glimepiride) alone or on a sulfonylurea (glimepiride) plus metformin, JANUVIA demonstrated a significant mean difference from placebo in A1C of 0.9 percent in patients on glimepiride and metformin and 0.6 percent in patients on glimepiride alone (p less than 0.001 for both comparisons to the addition of placebo).

After a titration/stabilization period on glimepiride (at least 4 mg/day) with or without metformin (at least 1500 mg/day) and a 2-week placebo run-in, 441 patients with a mean baseline A1C of 8.3 percent were randomized to the addition of JANUVIA 100 mg once-daily or placebo for 24 weeks. Of thes
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Hill-Rom Holdings, Inc. (NYSE: HRC ) will release ... 2011.  The company will host a webcast the following morning ... Earnings Release:   Hill-Rom,s Fiscal 2011 Third Quarter ... be issued to the public after the close of the ...
... 2011 U.S. Senators Jerry Moran ... established the first-ever Senate Community Pharmacy Caucus, an effort ... (NCPA). (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO) The ... pharmacy issues while serving as a clearinghouse of ideas ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 Third Quarter Earnings Webcast 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 3
(Date:4/16/2014)... Consider the marvel of the embryo. It begins as a ... they multiply to become the cells of our lungs, muscles, ... , Now, in a feat of reverse tissue engineering, Stanford ... that allows embryonic cells to proliferate and transform into all ...
(Date:4/16/2014)... known that fertility treatments are the leading cause of ... elevated risk of premature birth, these results are not ... Sterility . The article identifies six changes in ... multiple births and prematurity, including expanding insurance coverage for ...
(Date:4/15/2014)... the University of California, San Diego School of Medicine have ... C virus get liver disease and why the virus is ... , The hard-to-kill pathogen, which infects an estimated 200 million ... mitochondria dismantling the cell,s innate ability to fight infection. ...
(Date:4/14/2014)... one of the scientific marvels of the 20th century, ... won against bacterial infections. But scientists at the University ... to restoring its combat effectiveness, even against so-called "superbugs." ... of the penicillin family of drugs since their first ...
(Date:4/14/2014)... In a UT Dallas study involving serious youth offenders, the ... for the next seven years: "How long do you think ... the future encourages offending over time., Author Dr. Alex Piquero ... long life ahead of them offend at very high rates ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Breaking bad mitochondria 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 2Health News:Penicillin redux: Rearming proven warriors for the 21st century 3Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2
... , Exams can identify early signs of serious ... 18 Whether you are a college student having trouble seeing ... are fortunate not to be experiencing vision problems an annual eye ... experience a problem to schedule an appointment, but they may be ...
... , , SAN DIEGO, ... determine the effectiveness of its microwave ablation system for treating ... The studies using MedWaves, AveCure(TM) microwave coagulation-ablation system, which includes ... certified), are showing promising results. , , ...
... for the family dog , FRIDAY, Sept. 18 (HealthDay News) -- ... Call it a sort of empty-nest syndrome, except that the remaining ... the couch. , It,s not an uncommon scenario as canines across ... and back-to-school season. , "You,ve got to think of it ...
... , COLLEGEVILLE, Pa. and SAN DIEGO, Sept. 18 ... WYE ) and Ambrx Inc. today announced the formation of ... candidates for three undisclosed targets in multiple therapeutic areas. ... applying its protein medicinal chemistry platform to proteins produced in ...
... World Health Care Products Inc. (Pink Sheets: AVVH), a ... therapeutic, natural skin and health care products, announced the ... Care Products, Inc. is pleased to announce that updated ... With this release, the company anticipates that its status ...
... New York, Sept. 18 As ... activity across the U.S. ( http://www.cdc.gov/flu/weekly/ ). With ... ease parent,s minds? Communicate. , , Many schools ... like H1N1 to parents. According to a recent telephone poll ...
Cached Medicine News:Health News:AAA Members Save and Stay Healthy With Annual Eye Exams 2Health News:AAA Members Save and Stay Healthy With Annual Eye Exams 3Health News:MedWaves, Inc. Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation-Ablation System for Treatment of Tumors in Liver and Lung 2Health News:MedWaves, Inc. Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation-Ablation System for Treatment of Tumors in Liver and Lung 3Health News:MedWaves, Inc. Sponsors Investigational Studies to Evaluate Its Patented Microwave Thermal Coagulation-Ablation System for Treatment of Tumors in Liver and Lung 4Health News:Separation Anxiety, Canine-Style 2Health News:Separation Anxiety, Canine-Style 3Health News:Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances 2Health News:Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances 3Health News:Wyeth and Ambrx Form Multi-target Alliance to Leverage Recent Ambrx Biologics Platform Advances 4Health News:avVaa World Health Care Products, Inc. Announces Updated Financials 2Health News:When H1N1 Hits, Communication From Schools to Parents is Critical 2Health News:When H1N1 Hits, Communication From Schools to Parents is Critical 3
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
... the osteotomy staples is quite similar to the type ... inner position of the anti recoil contours and the ... There are 3 kinds of staples: 1. Straight ... staples can have 3 different widths: 20mm, 26 mm ...
A new generation of ORTHOMED S.A. fixation staples, manufactured from cobalt-chromium alloy: tried and test strength and tolerance...
Medicine Products: